Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

PURPOSE: Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Dise...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Kyriakopoulos, Christos E., Chen, Yu-Hui, Carducci, Michael A., Liu, Glenn, Jarrard, David F., Hahn, Noah M., Shevrin, Daniel H., Dreicer, Robert, Hussain, Maha, Eisenberger, Mario, Kohli, Manish, Plimack, Elizabeth R., Vogelzang, Nicholas J., Picus, Joel, Cooney, Matthew M., Garcia, Jorge A., DiPaola, Robert S., Sweeney, Christopher J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2018
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891129/
https://ncbi.nlm.nih.gov/pubmed/29384722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.3657
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak